3.51

3.85% 0.13

Voyager Therapeutics Inc (VYGR)

Overview News Price History Option Chain Financials Discussions Forecast

Voyager Therapeutics Inc stock is traded at $3.51, with a volume of 406.74K. It is up +3.85% in the last 24 hours and up +12.32% over the past month. Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.

Previous Close:

$3.38

Open:

$3.34

24h Volume:

406.74K

Relative Volume:

0.66

Market Cap:

$216.28M

Revenue:

$40.37M

Net Income/Loss:

$-119.72M

P/E Ratio:

-1.7204

EPS:

-2.0402

Net Cash Flow:

$-135.06M

1W Performance:

-0.85%

1M Performance:

+12.32%

6M Performance:

-15.01%

1Y Performance:

-9.54%

1-Day Range:

$3.3337

$3.515

1-Week Range:

$3.3337

$3.585

52-Week Range:

$2.935

$5.55

Voyager Therapeutics Inc Stock (VYGR) Company Profile

Name

Voyager Therapeutics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

857-259-5340

Address

75 HAYDEN AVENUE, LEXINGTON, MA

Employee

141

Twitter

@VoyagerTx

Next Earnings Date

2026-08-05

Latest SEC Filings

VYGR's Discussions on Twitter

Compare VYGR vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VYGR Voyager Therapeutics Inc	3.51	204.57M	40.37M	-119.72M	-135.06M	-2.0402
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-10-25	Initiated	Cantor Fitzgerald	Overweight
Dec-02-24	Initiated	Citigroup	Buy
Nov-29-24	Resumed	Wedbush	Outperform
Oct-16-24	Initiated	Leerink Partners	Outperform
Mar-26-24	Initiated	Guggenheim	Buy
Mar-19-24	Initiated	H.C. Wainwright	Buy
Mar-07-24	Initiated	Citigroup	Buy
Jan-02-24	Upgrade	Wells Fargo	Equal Weight → Overweight
May-10-23	Initiated	Truist	Buy
Mar-10-23	Initiated	Oppenheimer	Outperform
Oct-07-21	Upgrade	Robert W. Baird	Neutral → Outperform
Feb-26-21	Downgrade	Robert W. Baird	Outperform → Neutral
Feb-03-21	Downgrade	BTIG Research	Buy → Neutral
Feb-03-21	Downgrade	Wedbush	Outperform → Neutral
Dec-24-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Dec-23-20	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-11-20	Downgrade	Oppenheimer	Outperform → Perform
Nov-10-20	Downgrade	Raymond James	Strong Buy → Outperform
Nov-10-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Mar-19-20	Initiated	The Benchmark Company	Buy
Feb-06-20	Initiated	Oppenheimer	Outperform
Nov-15-18	Upgrade	Raymond James	Outperform → Strong Buy
Sep-10-18	Resumed	BTIG Research	Buy
Sep-10-18	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-04-18	Initiated	H.C. Wainwright	Buy
Mar-12-18	Downgrade	Evercore ISI	Outperform → In-line
Mar-12-18	Downgrade	Wedbush	Outperform → Neutral
Feb-02-18	Initiated	Morgan Stanley	Overweight
Nov-28-17	Resumed	Piper Jaffray	Overweight
Oct-31-17	Initiated	Robert W. Baird	Outperform
Oct-27-17	Initiated	Canaccord Genuity	Buy
Oct-23-17	Reiterated	Stifel	Buy
Oct-12-17	Initiated	Raymond James	Outperform
Aug-17-17	Initiated	Evercore ISI	Outperform
Jul-28-17	Resumed	Stifel	Buy

View All

Voyager Therapeutics Inc Stock (VYGR) Latest News

Aug 21, 2026

Voyager Therapeutics (NASDAQ:VYGR) Stock Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat

Aug 21, 2026

Aug 14, 2026

Voyager Therapeutics, Inc.: Financial Data Forecasts Estimates and Expectations | VT6 | US92915B1061 - marketscreener.com

Aug 14, 2026

Armistice Capital (VYGR) files 13G/A showing 3.44M Voyager Therapeutics shares - Stock Titan

Aug 14, 2026

Aug 13, 2026

Voyager to Advance 2 Tau-Targeted Alzheimer Therapies Toward Key Clinical Milestones - NeurologyLive

Aug 13, 2026

Voyager’s New Alzheimer’s Trial Puts VYGR on Investors’ Early Watchlist - TipRanks

Aug 13, 2026

CCORF Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $12 - Moomoo

Aug 13, 2026

Aug 12, 2026

Analysts Have Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Revenue Estimates By 47% - simplywall.st

Aug 12, 2026

HC Wainwright Brokers Raise Earnings Estimates for VYGR - MarketBeat

Aug 12, 2026

Aug 11, 2026

Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst - The Globe and Mail

Aug 11, 2026

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and Teleflex (TFX) - The Globe and Mail

Aug 11, 2026

Aug 10, 2026

Voyager Therapeutics (NASDAQ:VYGR) Earns Buy Rating from HC Wainwright - MarketBeat

Aug 10, 2026

VYGR Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus

Aug 10, 2026

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - moomoo.com

Aug 10, 2026

The Voyager Therapeutics, Inc. (NASDAQ:VYGR) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - simplywall.st

Aug 10, 2026

Aug 08, 2026

Voyager Therapeutics (VYGR) Stock Rebounds While Cash Runway Concerns Persist - Sahm

Aug 08, 2026

Aug 07, 2026

Voyager Therapeutics Inc earnings beat by $0.10, revenue fell short of estimates - Investing.com Nigeria

Aug 07, 2026

Wedbush Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $8 - Moomoo

Aug 07, 2026

Is Voyager Therapeutics Inc (VYGR) Overvalued After Q2 Earnings - GuruFocus

Aug 07, 2026

Voyager Therapeutics (NASDAQ:VYGR) Issues Quarterly Earnings Results - MarketBeat

Aug 07, 2026

Aug 06, 2026

Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance

Aug 06, 2026

VYGR Looks 86.3% Overvalued on GF Value™ - GuruFocus

Aug 06, 2026

Voyager Therapeutics: Q2 Earnings Snapshot - Yahoo Finance

Aug 06, 2026

Voyager Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 06, 2026

Voyager Reports Second Quarter 2026 Financial and Operating Results - The Manila Times

Aug 06, 2026

Voyager Therapeutics reports Q2 2026 net loss $24.5M, cash $148.8M; runway into 2028 - tradingview.com

Aug 06, 2026

Voyager Therapeutics Q2 collaboration revenue falls, net loss narrows - TradingView

Aug 06, 2026

Voyager Therapeutics (Nasdaq: VYGR) gains FDA IND clearance for VY1706 - Stock Titan

Aug 06, 2026

VOYAGER THERAPEUTICS Q2 COLLABORATION REVENUE USD 3.165 MILLION - Moomoo

Aug 06, 2026

Voyager Therapeutics (VYGR) Edges Higher by 1.45% as Shares Defend $2.99 SupportFibonacci Arc - dars.gov.et

Aug 06, 2026

Jul 31, 2026

Voyager Therapeutics Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView

Jul 31, 2026

Jul 29, 2026

Voyager Therapeutics (VYGR) to Announce Quarterly Earnings on Wednesday - MarketBeat

Jul 29, 2026

Jul 27, 2026